EGF and asthma: As predicted, treatment with a DP2 antagonist in the absence of a RV-induced exacerbation (akin to ‘stable’ asthma) failed to affect ASM area, collagen deposition, TGF-β1 or EGF expression (Supplementary Fig. S2A–F).